ALPCO Diagnostics
Founded in 1991 as the American Laboratory Products Company, ALPCO has evolved from a distributor into a leading global diagnostics firm. Its strategic merger with GeneProof in April 2022 significantly expanded its capabilities in molecular diagnostics. The company now provides integrated platforms for immunodiagnostics and PCR-based molecular diagnostics, serving clinical and research laboratories with high-quality, automated testing solutions.
Private Company
Total funding raised: $148.6M
AI Company Overview
Founded in 1991 as the American Laboratory Products Company, ALPCO has evolved from a distributor into a leading global diagnostics firm. Its strategic merger with GeneProof in April 2022 significantly expanded its capabilities in molecular diagnostics. The company now provides integrated platforms for immunodiagnostics and PCR-based molecular diagnostics, serving clinical and research laboratories with high-quality, automated testing solutions.
Technology Platform
ALPCO's core technology spans automated sample-to-answer platforms for both immunodiagnostics (multiplex allergy, chemiluminescence) and molecular diagnostics (PCR-based extraction and detection). This includes the GeneProof myCROBE/croBEE systems, the MADx ALEX/FOX allergy platforms, and the KleeYa chemiluminescence instrument.
Funding History
135Opportunities
Risk Factors
Competitive Landscape
ALPCO competes in specialized niches against giants like Thermo Fisher, Roche, and Abbott, as well as focused players like Bühlmann, Cepheid, and Qiagen. Its differentiation lies in its integrated offering of both immunodiagnostic and molecular diagnostic automated platforms, targeting the specific needs of mid-volume clinical and research laboratories seeking sample-to-answer solutions.